Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,035.81 +17.42 (+0.35%) Dow
38,047.39 +144.10 (+0.38%) Nasdaq
15,723.39 +117.91 (+0.76%) Bitcoin USD
59,041.73 +2,080.58 (+3.65%) CMC Crypto 200
1,273.60 +2.86 (+0.22%)
Tenax Therapeutics, Inc. (TENX)
| Previous close | 3.9000 |
| Open | 3.9700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.7201 - 3.9700 |
| 52-week range | 3.4700 - 61.2000 |
| Volume | |
| Avg. volume | 361,486 |
| Market cap | 7.363M |
| Beta (5Y monthly) | 2.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -31.0400 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.50 |
GlobeNewswireTenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEFProvides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040Expressly provides IP protection for levosimendan at all therapeutic doses for use in PH-HFpEF Expressly provides IP protection for levosimendan in combination with various cardiovascular drugs for use in PH-
- GlobeNewswire
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role for levosimendan in treating this prevalent, fatal disease Experts will explain pathophysiology of PH-HFpEF, and mechanistic rationale for levosimendan Update on the ongoing Phase 3 LEVEL Study evaluating TNX-103 (oral levosimendan) for the treatment of PH-HFpEF Tena
- GlobeNewswire
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S. Intellectual Property Covering the Use of Levosimendan for the Treatment of PH-HFpEF and for Use in Combination with Other Cardiovascular Therapies The Company Secured Global Commercial Rights to Levosimendan for the Treatment of PH-HFpEFThe Company will host a KOL Event, “LEVEL Setting: Th
